Developing a new standard of care for patients with nonmetastatic Esophageal and Gastric cancers – the latest study review by BIOMEDICA CRO
Immunotherapy has transformed treatment for patients with stage 4 metastatic Esophageal and Gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients’ tumors exhibit a high expression of an immune-related protein called PD-L1.
Researchers are now investigating whether immunotherapy benefits patients who do not have stage 4 metastatic disease. In these patients, tumors have not spread to distant organs according to the latest study.
Harry Yoon, M.D., a medical oncologist at Mayo Clinic Cancer Center and his colleagues performed a clinical trial to evaluate whether adding immunotherapy called pembrolizumab to standard chemoradiation and surgery for patients with Gastroesophageal Junction Adenocarcinoma might increase the number of patients who experienced complete tumor eradication in the original location and in nearby lymph nodes.
“We found that adding immunotherapy appeared to increase the likelihood of complete eradication of the primary tumor and regional nodal metastases in the group of patients whose tumors expressed high levels of PD-L1,” says Dr. Yoon.
Dr. Yoon notes: “If these results can be confirmed in a larger, separate clinical trial, the combination of immunotherapy with standard-of-care chemoradiation and surgery could become the new standard of care for patients with nonmetastatic Gastroesophageal cancer”.
Please find more information in the Clinical Cancer Research journal, research article, Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction”.
BIOMEDICA CRO is honored to participate in preclinical trials, research on new biomarkers, screening tests and drug discovery. We have extensive experience in collecting various human biospecimens for scientists all over the world.
Our primary area is oncology studies (Breast, Colorectal, Prostate, Esophageal, Gastric cancers, etc.). In addition, we have contracted 50+ sites and departments with different disease areas.
Please email us at office@biomedica-cro.com / LinkedIn to receive high-quality human biospecimens and associated data for your studies.
